NCT04323072

Brief Summary

Laparoscopic sleeve gastrectomy (LSG) is currently the most frequent primary bariatric procedure performed worldwide. LSG is safe and effective in terms of excess weight loss. It is a powerful metabolic operation that activates significant hormonal pathways that lead to changes in eating behaviour, glycemic control and intestinal functions. LSG is easier regarding its technical aspects and does not need any intestinal anastomosis, begin limited to the stomach. The most frequent and sometimes dangerous complications are leaking, haemorrhage, splenic injury, sleeve stenosis and gastroesophageal reflux. Despite its established efficacy and safety, controversy still exists on optimal operative technique for LSG: bougie size, the distance of resection margin from the pylorus, the shape of the section at the gastroesophageal junction, staple line reinforcement and intraoperative leak testing is among the most controversial issues 11\[6\]. In literature, different authors have adopted a resection distance from the pylorus between 2 and 6-7 cm with various reasons 11\[6\]. Resections more distant to the pylorus improve gastric emptying, prevent distal stenosis and reduce intraluminal pressure, potentially leading to a lower incidence of fistula and/or reflux. On the other hand, resections close to the pylorus would reduce gastric distensibility and increase intragastric pressure, potentially increasing satiety with less oral intake 11(11,12). The primary aim of this randomized monocentric study is to evaluate %EWL at 1 and 2 years follow-up after LSG in two Groups: Group A with a gastric resection starting from 2 cm from the pylorus with therefore a wide antrectomy and Group B with a gastric resection starting from 6 cm from the pylorus with therefore a small antrectomy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
150

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Mar 2015

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

March 1, 2015

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2017

Completed
3.2 years until next milestone

First Submitted

Initial submission to the registry

March 18, 2020

Completed
8 days until next milestone

First Posted

Study publicly available on registry

March 26, 2020

Completed
Last Updated

March 26, 2020

Status Verified

March 1, 2020

Enrollment Period

1.8 years

First QC Date

March 18, 2020

Last Update Submit

March 24, 2020

Conditions

Outcome Measures

Primary Outcomes (8)

  • Postoperative weight and height combined to report BMI in kg/m^2

    Change of weight and height expressed in Postoperative Body Mass Index obtained by dividing the weight by the squared height expressed in meters (kg/m2)

    3 months

  • Postoperative weight and height combined to report BMI in kg/m^2

    Change of weight and height expressed in Postoperative Body Mass Index obtained by dividing the weight by the squared height expressed in meters (kg/m2)

    6 months

  • Postoperative weight and height combined to report BMI in kg/m^2

    Change of weight and height expressed in Postoperative Body Mass Index obtained by dividing the weight by the squared height expressed in meters (kg/m2)

    12 months

  • Postoperative weight and height combined to report BMI in kg/m^2

    Change of weight and height expressed in Postoperative Body Mass Index obtained by dividing the weight by the squared height expressed in meters (kg/m2)

    24 months

  • Postoperative percentage excess weigth loss

    Change of weight expressed in percentage of excess weight loss postoperatively at follow-up

    3 months

  • Postoperative percentage excess weigth loss

    Change of weight expressed in percentage of excess weight loss postoperatively at follow-up

    6 months

  • Postoperative percentage excess weigth loss

    Change of weight expressed in percentage of excess weight loss postoperatively at follow-up

    12 months

  • Postoperative percentage excess weigth loss

    Change of weight expressed in percentage of excess weight loss postoperatively at follow-up

    24 months

Secondary Outcomes (6)

  • Gastroesophageal reflux disease(GERD)

    at 12 months

  • Gastroesophageal reflux disease(GERD)

    at 24 months

  • Gastroesophageal reflux disease symptoms

    at 3 months

  • Gastroesophageal reflux disease symptoms

    at 6 months

  • Gastroesophageal reflux disease symptoms

    at 12 months

  • +1 more secondary outcomes

Study Arms (2)

Group A

EXPERIMENTAL

Resection of antrum proximally 2 cm to the pylorus

Procedure: Wide antrectomy

Group B

ACTIVE COMPARATOR

Resection of antrum proximally 6 cm to the pylorus

Procedure: Smal antrectomy

Interventions

The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 2 cm.

Group A

The starting point of resection of the stomach from the pylorus to begin the gastrectomy is 6 cm.

Group B

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • informed consent.
  • morbid obesity defined as body mass index (BMI) 40 kg/m2

You may not qualify if:

  • previous bariatric surgical procedures,
  • endocrine disorders causing obesity
  • pregnancy or lactation
  • psychiatric illness
  • inflammatory bowel disease
  • Barrett ́s oesophagus
  • severe GERD with esophagitis B and C
  • a large hiatal hernia (\>5 cm)
  • GERD-HRQLscore \> 25 dietary restriction despite

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Francdesco Pizza

Napoli, Naples, 80035, Italy

Location

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Head of the bariatric and metabolic surgery unit

Study Record Dates

First Submitted

March 18, 2020

First Posted

March 26, 2020

Study Start

March 1, 2015

Primary Completion

January 1, 2017

Study Completion

January 1, 2017

Last Updated

March 26, 2020

Record last verified: 2020-03

Data Sharing

IPD Sharing
Will not share

Locations